Meridian Bioscience, Inc. (VIVO) Misses Q2 EPS by 2c, Reiterates Outlook
Tweet
Share
E-mailGet Alerts VIVO Hot Sheet
Join SI Premium – FREE
Meridian Bioscience, Inc. (NASDAQ: VIVO) reported Q2 EPS of $0.18, $0.02 worse than the analyst estimate of $0.20. Revenue for the quarter came in at $41.1 million versus the consensus estimate of $41.2 million.
Meridian Bioscience, Inc. is reiterating its guidance and sees FY2011 EPS of $0.77-$0.82, versus the consensus of $0.78. Meridian Bioscience, Inc. sees FY2011 revenue of $165-$170 million, versus the consensus of $165.55 million.
Meridian Bioscience, Inc. is reiterating its guidance and sees FY2011 EPS of $0.77-$0.82, versus the consensus of $0.78. Meridian Bioscience, Inc. sees FY2011 revenue of $165-$170 million, versus the consensus of $165.55 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kroger (KR) Reports In-Line Q1 EPS, Beats on Revenue; Offers FY27 EPS Guidance
- Primoris cuts 2026 outlook on renewables cost overruns, COO exits
- John Wiley & Sons, Inc. (WLYB) Tops Q4 EPS by 12c; Offers Outlook
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
